Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
82.1M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
43.1M
-
Shares change
-
+1.87M
-
Total reported value, excl. options
-
$1.1B
-
Value change
-
+$41M
-
Put/Call ratio
-
0.29
-
Number of buys
-
81
-
Number of sells
-
-50
-
Price
-
$25.44
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q1 2023
162 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q1 2023.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.1M shares
of 82.1M outstanding shares and own 52.49% of the company stock.
Largest 10 shareholders include BlackRock Inc. (2.77M shares), VR Adviser, LLC (2.7M shares), STATE STREET CORP (2.4M shares), COMMODORE CAPITAL LP (2.19M shares), VANGUARD GROUP INC (2.13M shares), Paradigm Biocapital Advisors LP (2.09M shares), RA CAPITAL MANAGEMENT, L.P. (2.01M shares), PERCEPTIVE ADVISORS LLC (1.74M shares), Vivo Capital, LLC (1.68M shares), and Fairmount Funds Management LLC (1.37M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.